Paper Details

  1. Home
  2. Paper Details

Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management.

Author: BergerThomas, BstehGabriel, HartungHans-Peter, KrajncNik, MaresJan

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Monoclonal antibodies are a mainstay in the treatment of relapsing multiple sclerosis, with some benefit for primary progressive MS. They target molecules on cells involved in MS immune mechanisms, preventing leukocyte migration (natalizumab) or eliminating pathogenic cell populations (alemtuzumab, rituximab, ocrelizumab, ofatumumab, and ublituximab). While effective, they have serious side effects like infections, autoimmune diseases, malignancies, and infusion/injection reactions, requiring careful patient selection and monitoring. Their long half-life benefits infrequent dosing but creates challenges for vaccination and family planning.
Paper Details　
Original Abstract of the Article :
Monoclonal antibodies have become a mainstay in the treatment of patients with relapsing multiple sclerosis (RMS) and provide some benefit to patients with primary progressive MS. They are highly precise by specifically targeting molecules displayed on cells involved in distinct immune mechanisms of...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978776/

データ提供：米国国立医学図書館（NLM）

Monoclonal Antibodies: A New Era in Relapsing Multiple Sclerosis Treatment

Relapsing multiple sclerosis (RMS) is a challenging autoimmune disease that affects the central nervous system. This research provides an overview of monoclonal antibodies, a class of drugs that have revolutionized the treatment of RMS. It's like a camel caravan discovering a new and promising oasis in the vast desert of MS research.

Precision Targeting: A New Approach to MS Treatment

Monoclonal antibodies offer a highly precise approach to treating RMS, specifically targeting molecules involved in the disease's pathophysiology. They work by inhibiting the migration of immune cells across the blood-brain barrier or by eliminating specific immune cells. It's like using a precise compass to navigate through the intricate pathways of the immune system, selectively targeting the root of the problem.

Navigating the Complexities of Monoclonal Antibody Therapy

While monoclonal antibodies offer promising benefits, they also carry potential risks, including infections, secondary autoimmune diseases, and malignancies. Careful patient selection, close monitoring, and appropriate risk management strategies are essential to ensure safe and effective treatment. It's like carefully navigating a desert terrain, being aware of potential dangers and taking necessary precautions to ensure a safe and successful journey.

Dr.Camel's Conclusion

Monoclonal antibodies represent a significant advancement in the treatment of RMS, offering a new era of precision targeting and personalized care. By carefully navigating the complexities of this therapy and taking appropriate precautions, healthcare professionals can empower patients to achieve a better quality of life. It's like finding a new oasis in the vast desert of MS research, offering hope and promise for a brighter future for those living with this challenging condition.

Date :
  1. Date Completed 2022-07-21
  2. Date Revised 2022-07-27
Further Info :

Pubmed ID

35378683

DOI: Digital Object Identifier

PMC8978776

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.